Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CF PharmTech, Inc.

長風藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2652)

CHANGE IN BOARD LOT SIZE

The board (the "Board") of directors (the "Directors") of CF PharmTech, Inc. (the "Company") announces that the board lot size of its H Shares (the "H Shares") for trading on The Stock Exchange of Hong Kong Limited (the "Stock Exchange") will be changed from 500 H Shares to 100 H Shares with effect on Tuesday, July 14, 2026 at 9:00 a.m.

The H Shares are currently traded in board lots of 500 H Shares each. The Board expects that the reduction in board lot size will lower the threshold for investors to purchase the H Shares, thus facilitating the trading and improving the liquidity of the H Shares, which will enable the Company to attract more investors and therefore broaden the shareholders' base of the Company. Upon the change in board lot size becoming effective, the H Shares shall be traded in board lots of 100 H Shares each. Based on the closing price of HK$18.77 per H Share as quoted on the Stock Exchange as at the date of this announcement, the market value of each board lot of the H Shares before the change in board lot size is HK$9,385 and will be HK$1,877 after the change in board lot size.

The change in board lot size will not result in any change in the relative rights of the shareholders. As no odd lots of the H Shares will result from the aforesaid change in board lot size, no odd lot arrangement is required to be made to match the sales and purchases of odd lots. The Board considers that the change in board lot size is in the interest of the Company and its shareholders as a whole.

2

EXPECTED TIMETABLE

The expected timetable for the change in board lot size is set out below:

EXCHANGE OF NEW H SHARE CERTIFICATES

Shareholders of H Shares may submit their existing H Share certificates in board lots of 500 H Shares each to the H Share Registrar, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong, in exchange for new H Share certificates in board lots of 100 H Shares each, free of charge, during business hours from 9:00 a.m. to 4:30 p.m. from Monday, June 29, 2026 to Wednesday, August 5, 2026 (both dates inclusive). After the expiry of such period, any exchange of H Share certificates will be accepted only on payment of a fee of HK$2.50 (or such higher amount as may from time to time be specified by the Stock Exchange) for each new H Share certificate in board lots of 100 H Shares issued or each existing H Share certificate in board lots of 500 H Shares submitted for cancellation, whichever number of H Share certificates involved is higher. It is expected that the new H Share certificates will be available for collection from the H Share Registrar within 10 business days after delivery of the existing H Share certificates to the H Share Registrar for exchange. Save for the change in the number of H Shares represented by each board lot, the new H Share certificates will have the same design and colour as the existing H Share certificates.

As from Tuesday, July 14, 2026, all new H Share certificates will be issued in board lots of 100 H Shares each. All existing H Share certificates in board lots of 500 H Shares each will continue to be good evidence of title to such H Shares and be valid for delivery, trading and settlement purposes.

By Order of the Board
CF PharmTech, Inc.
長風藥業股份有限公司
Dr. LIANG Bill Wenqing
Chairperson, Executive Director and Chief Executive Officer

Hong Kong, June 22, 2026

As at the date of this announcement, the Board comprises Dr. LIANG Bill Wenqing, Dr. LI LI BOVET, Dr. LI Qi and Ms. ZHU Yuyu as executive Directors, Mr. CAI Lei and Dr. YI Hua as non-executive Directors, and Dr. JIN Jian, Ms. WANG Lijuan, Mr. WEI Shirong and Mr. IP Wang Hoi as independent non-executive Directors.

3